700 Billion Won Raised for New Drug Development, Redirected to New Ventures
Court: "Significant Social Harm... Betrayed Market Trust"

Cho Dae-woong, former CEO of Cellivery, the first company to be listed under the “special listing for growth potential” system, has been sentenced to 15 years in prison and taken into custody in court after being found guilty of raising over 70 billion won through false disclosures.


Seoul Southern District Court. Photo by Jiye Lee

Seoul Southern District Court. Photo by Jiye Lee

View original image

On August 20, the 14th Criminal Division of the Seoul Southern District Court (Chief Judge Lee Jeonghee) sentenced former CEO Cho, who was indicted and detained on charges of fraudulent unfair trading under the Capital Markets Act, to 15 years in prison and a fine of 210 billion won. The court also ordered the forfeiture of 510 million won. As a result, Cho, who had been released on bail in July last year, was taken back into custody. Kwon, an inside director who was tried together on the same charges, received a sentence of five years in prison and a fine of 110 billion won.


Cho and others were put on trial on charges of raising approximately 70 billion won through the issuance of convertible bonds in September 2021, claiming publicly that the funds would be used for new drug research and development, while in fact acquiring a wet tissue manufacturing company and lending more than 20 billion won to that company.


Cho is also accused of using undisclosed information in March 2023, when he knew in advance that Cellivery would be designated as an “administrative issue” and face a trading suspension, selling his shares to avoid losses exceeding 500 million won.


The court stated, "The crimes committed by the defendants are severe offenses that greatly undermine public trust in information and the fairness of transactions in the capital market," and added, "It not only caused unexpected losses to investors, but also led to distrust of both the market and companies, shaking the very foundation of the market economy." The court particularly emphasized that, as Cellivery was the first company in Korea to receive a special listing for growth potential, a high level of legal compliance and responsible management was required, yet it betrayed the trust of both investors and the market.


Regarding Cho, the court explained that, "As the company’s highest decision-maker, given the method, duration, and amount of the crimes, his responsibility is exceedingly heavy," and noted, "Even when Cellivery failed to generate significant revenue after its listing, instead of making efforts toward corporate growth and business normalization, he used corporate credit cards for personal purposes and did not fulfill the responsibilities required of a CEO."


However, the court did take into account as favorable factors that most of the funds raised through the crimes were used for acquiring subsidiaries and pursuing new businesses, and that Cho invested a significant amount of his personal assets into the company.


Cellivery entered the KOSDAQ market in November 2018 as the first Korean company to use the “special listing for growth potential” scheme, which gives companies with high potential, but insufficient business performance, the opportunity to go public. Cellivery drew market attention with its efforts to develop new drugs for Parkinson’s disease and COVID-19, but after receiving a disclaimer of opinion from its auditor and experiencing total capital impairment, the company was delisted last year.



Previously, prosecutors had demanded 30 years in prison and a fine of 250 billion won for former CEO Cho, and seven years in prison and a fine of 250 billion won for Kwon during final arguments.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing